Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 11/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | USP2 | O75604 | 2/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | HTT | P42858 | 2/20 | 0.73 |
| ▸ | NPC1 | O15118 | 1/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.73 |
| ▸ | RECQL | P46063 | 1/20 | 0.73 |
| ▸ | RAB9A | P51151 | 1/20 | 0.73 |
| ▸ | BLM | P54132 | 1/20 | 0.73 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | MYC | P01106 | 1/20 | 0.59 |
| ▸ | UHRF1 | Q96T88 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | RAD52 | P43351 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL396290 | 0.99 | APEX1 (0.74) | APEX1MEN1KMT2AUSP2KDM4E | |
| SCHEMBL13735656 | 0.89 | APEX1 (0.83) | APEX1MEN1KMT2AUSP2KDM4E | |
| SCHEMBL13058121 | 0.88 | APEX1 (0.76) | APEX1MEN1KMT2AUSP2KDM4E | |
| SCHEMBL1495163 | 0.86 | APEX1 (0.77) | APEX1MEN1KMT2AUSP2KDM4E | |
| SCHEMBL1494905 | 0.85 | APEX1 (1.00) | APEX1MEN1KMT2AUSP2KDM4E | |
| SCHEMBL3751792 | 0.84 | APEX1 (0.75) | APEX1MEN1KMT2AUSP2KDM4E | |
| SCHEMBL13734656 | 0.83 | APEX1 (0.81) | APEX1MEN1KMT2AUSP2KDM4E | |
| SCHEMBL13832373 | 0.83 | APEX1 (1.00) | APEX1MEN1KMT2AUSP2KDM4E | |
| SCHEMBL1494752 | 0.82 | APEX1 (0.77) | APEX1MEN1KMT2AUSP2KDM4E | |
| SCHEMBL23528082 | 0.82 | APEX1 (0.80) | APEX1MEN1KMT2AUSP2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101580-B2 | Therapeutic agent for irritable bowel syndrome | ASTELLAS PHARMA INC. (JP) | 2012-01-24 | — | — | US | claimed |
| US-20090093415-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | ASTELLAS PHARMA INC. (JP) | 2009-04-09 | — | — | US | claimed |
| EP-1872795-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | Astellas Pharma Inc. (JP) | 2008-01-02 | — | — | EP | claimed |
| US-8101580-B2 | Therapeutic agent for irritable bowel syndrome | ASTELLAS PHARMA INC. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-8101580-B2 | Therapeutic agent for irritable bowel syndrome | ASTELLAS PHARMA INC. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-8101580-B2 | Therapeutic agent for irritable bowel syndrome | ASTELLAS PHARMA INC. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-20090093415-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | ASTELLAS PHARMA INC. (JP) | 2009-04-09 | — | — | US | disclosed |
| US-20090093415-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | ASTELLAS PHARMA INC. (JP) | 2009-04-09 | — | — | US | disclosed |
| US-20090093415-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | ASTELLAS PHARMA INC. (JP) | 2009-04-09 | — | — | US | disclosed |
| EP-1872795-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | Astellas Pharma Inc. (JP) | 2008-01-02 | — | — | EP | disclosed |
| EP-1872795-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | Astellas Pharma Inc. (JP) | 2008-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093415-A1 | THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME | BRS3, VIPR2, BDKRB2 | APEX1 4874/4885MEN1 2918/4885KMT2A 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.